Loading...

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD

INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD). METHODS: This was a phase III, active-control...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Kidney Int Rep
Main Authors: Akizawa, Tadao, Iwasaki, Manabu, Otsuka, Tetsuro, Yamaguchi, Yusuke, Reusch, Michael
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2021
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258605/
https://ncbi.nlm.nih.gov/pubmed/34307976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.003
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!